Valion Bio, Inc. (VBIO) research

Valion Bio, Inc.

Sector: Healthcare
Industry: Biotechnology
Last price: $2.59
As of: 2026-10-02

Valion Bio, Inc. (VBIO): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-01.

As of 2026-10-01, the latest of: this ticker's 13F holdings load, its latest SEC filing date, and its latest signal other than 13F-derived signals. Source: SEC EDGAR filings for VBIO. Method and limitations.

COMPANY DOSSIER

See the full VBIO dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for VBIO on one page. Preview it with sample data, then open it live with a free account.

Preview the VBIO dossier

Active signals for VBIO

mediumNEW_POSITION2026-08-16
CITADEL ADVISORS LLC new position in VBIO
All 2026-08-16 signals →
mediumEARNINGS_BEAT2026-06-21
Q4-2022: Beat consensus by 27.5% - EPS $-289 vs $-398.82 estimate
All 2026-06-21 signals →
mediumEARNINGS_BEAT2026-06-21
Q2-2023: Beat consensus by 14.2% - EPS $-119 vs $-138.72 estimate
All 2026-06-21 signals →
mediumEARNINGS_BEAT2026-06-21
Q3-2023: Beat consensus by 79.3% - EPS $-25.16 vs $-121.38 estimate
All 2026-06-21 signals →
mediumEARNINGS_BEAT2026-06-21
Q2-2024: Beat consensus by 94.8% - EPS $-0.32 vs $-6.12 estimate
All 2026-06-21 signals →

FREE, NO ACCOUNT

Every signal on VBIO, as it fires

You are seeing 5 of 9 signals recorded on VBIO since 2026-05-26.

The five above landed across 2 days. The other 4 were recorded on 1 other days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in VBIO (2026Q2)

Manager / security	Market value	% portfolio	QoQ
CITADEL ADVISORS LLCCUSIP 888705308 · 2026Q2	$39K	0.00%	,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, VBIO

8-K2026-10-01
SEC EDGAR ↗
8-K2026-09-23
SEC EDGAR ↗
8-K2026-09-01
SEC EDGAR ↗
8-K2026-08-27
SEC EDGAR ↗
8-K2026-08-17
SEC EDGAR ↗
10-Q2026-08-14
SEC EDGAR ↗
8-K2026-08-06
SEC EDGAR ↗
8-K2026-07-14
SEC EDGAR ↗
8-K2026-06-18
SEC EDGAR ↗
8-K2026-06-03
SEC EDGAR ↗

VBIO against its peers

VBIO's return on equity of -52.9% ranks in the 95th percentile of 10 Biotechnology sub-industry peers, fiscal periods ending between 2025-10-31 and 2026-03-31.

Metric	VBIO	Peer median	Percentile	n
Revenue FY	n/a	101551	n/a	8
Operating margin	n/a	-5937.0%	n/a	7
Net margin	n/a	-5863.5%	n/a	7
Return on equity	-52.9%	-209.0%	95	10

Peers (18): PPBT, ARTL, MTNB, GNPX, VSBC, ISCO, TCRT, CASIF, CMND, BCAB, OGEN, ABPO, CLDI, CRIS, SILO, HCWB, VIVS, ACUT. Left out: BIXT (no annual filing), GPLL (period gap), VCNX (period gap), LABT (no annual filing), LSBCF (period gap), XRTX (no annual filing), VRAX (period gap). Fiscal periods ending between 2025-10-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (VBIO: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more VBIO signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to VBIOand get the insider, 13F, options, and confluence read in one view.